DPYDGenotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer

Authors:

Abstract
Since the 1990s, fluorouracil-based adjuvant chemotherapy has been the standard of care for patients with stage III colon cancer (CC) after curative surgical resection. The MOSAIC study1 showed significant improvements in disease-free survival and overall survival in patients with stage III CC receiving infused fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) compared with fluorouracil and leucovorin alone, with 5-year disease-free survival of 66.4% and 6-year overall survival of 72.9% in the experimental group. This degree of benefit was confirmed by the NSABP C-07 study2 in patients receiving FLOX (bolus fluorouracil, leucovorin, and oxaliplatin) compared with those receiving bolus fluorouracil and leucovorin alone. As in the metastatic setting, the addition of oxaliplatin to fluorouracil therefore results in better efficacy compared with fluorouracil alone but also increases overall and severe adverse events (AEs).1,3